HELP Copays Act
Summary
The HELP Copays Act (S.864) would require group health plans to count financial assistance from drug manufacturers and non-profits toward patient deductible and out-of-pocket limits. The bill is in committee with 26 cosponsors and a companion House bill. If enacted, it would benefit pharmaceutical companies by boosting drug utilization, while insurers face higher claims costs. No market data is provided, but structural impacts are clear.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The HELP Copays Act would mandate counting manufacturer copay assistance toward patient deductibles and OOP max, boosting drug utilization.
- 2.Pharmaceutical companies (LLY, MRK, PFE, ABBV, JNJ) are primary beneficiaries with estimated 1-3% revenue uplift.
- 3.Health insurers (UNH) face increased drug claim costs, but the impact is mitigated by PBM capabilities and represents a small percentage of total revenue.
Market Implications
The HELP Copays Act directly impacts healthcare sector dynamics. Pharmaceutical companies with strong branded drug portfolios (LLY, MRK, PFE, ABBV, JNJ) could see modest revenue gains if the bill passes, due to improved effectiveness of copay cards. Insurers like UNH may face higher medical costs but the impact is small relative to their scale. No market price data is available, but the structural bias is positive for pharma and slightly negative for insurers.
Full Analysis
The HELP Copays Act (S.864) was introduced on March 5, 2025 by Sen. Roger Marshall (R-KS) and has 26 cosponsors including both parties. Hearings were held in the Senate HELP Committee on March 19, 2026. The bill amends the Public Health Service Act to require that amounts paid by or on behalf of individuals—including financial assistance from non-profit organizations and prescription drug manufacturers—count toward the deductible, coinsurance, copayment, and out-of-pocket limit. A companion bill (HR6423) has been introduced in the House. The bill is still in committee and has not passed either chamber.
The legislation involves no direct government funding; it is a regulatory mandate on private health insurance plans. The money trail runs through insurance claims: by counting manufacturer copay assistance toward out-of-pocket limits, patients will hit their deductibles and maximums faster, increasing insurer liability for drug costs. Pharmaceutical companies benefit because patients are more likely to fill prescriptions when copay assistance is effective, boosting sales volume.
No convergence signals are present in the provided data. The bill stands alone as a targeted health policy initiative.
Structural winners are pharmaceutical companies with high-priced branded drugs that use copay assistance programs: $LLY (revenue $34.1B), $MRK ($60.1B), $PFE ($59.6B), $ABBV ($54.3B), ($85.2B). For these, the bill enhances their existing patient assistance programs, potentially increasing net revenue by 1-3% depending on drug mix. Structural losers are health insurers: (revenue $371.6B) faces higher drug claim costs, though its Optum PBM may offset some impact through formulary adjustments. The net effect on UNH is bearish but moderate given its diversified business.
Timeline: The bill has advanced from introduction to hearings, indicating active committee work. However, it has not yet passed the Senate. The next steps are committee markup and then a floor vote. The companion House bill adds momentum but passage this Congress is uncertain. Legislative velocity is moderate.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Requires health plans to count manufacturer copay assistance toward patient deductible and out-of-pocket maximum.
Who must act
Group health plans and health insurance issuers covered under PHS Act.
What happens
Reduces effective patient cost-sharing for branded drugs, increasing prescription fill rates and adherence.
Stock impact
LLY's key drugs (Mounjaro, Zepbound) have high list prices and rely on copay cards; this bill enhances their effectiveness, likely boosting net revenue by 1-3%.
What the bill does
Requires health plans to count manufacturer copay assistance toward patient deductible and out-of-pocket maximum.
Who must act
Group health plans and health insurance issuers covered under PHS Act.
What happens
Reduces effective patient cost-sharing for branded drugs, increasing prescription fill rates and adherence.
Stock impact
MRK's branded drugs (Keytruda, Gardasil) benefit from improved copay assistance pass-through; revenue impact estimated at 1-2% of pharma revenue.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Wildlife Health Coordination and Zoonotic Disease Prevention Act of 2026
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model".
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Biosimilar Red Tape Elimination Act
To amend the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to require health insurance coverage of drugs indicated for the treatment of autoimmune diseases and certain blood disorders.
INSULIN Act of 2026
TREAT PTSD VA Act
Maternal Health Pandemic Response Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →